Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors

Trial Profile

A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Colorectal cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 04 Jun 2019 According to a Northwest Biotherapeutics media release, follow-up data from the trial was presented in the Industry Expert Theater presentation at the 55th annual ASCO Conference 2019.
    • 17 Jul 2018 Results (n=39) from part 1 of this trial published in the Clinical Cancer Research
    • 29 May 2018 According to a Northwest Biotherapeutics media release, company has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top